Liposomal Bupivacaine Doesnt Decrease Pain After

A study published in The Journal of Bone & Joint Surgery found that intraoperative use of liposomal bupivacaine does not improve pain scores or other outcomes for older adults undergoing hemiarthroplasty for hip fractures, compared to conventional bupivacaine. The randomized trial, conducted by researchers at Maimonides Medical Center, involved 50 older adults and assessed pain scores, opioid doses, and time to ambulate. Results showed no significant difference in pain scores or opioid requirements between the two groups. The study also highlighted the high cost of liposomal bupivacaine, which is 11 times more expensive than standard bupivacaine or other postoperative pain modalities. Researchers concluded that the use of liposomal bupivacaine in geriatric patients with hip fractures undergoing hemiarthroplasty warrants further questioning due to its increased costs. The study adds to the growing body of evidence that liposomal bupivacaine may not be beneficial in the context of primary total joint arthroplasty. Wolters Kluwer, the publisher of the study, provides clinical technology and solutions for various healthcare, tax, accounting, legal, and corporate compliance sectors.

Source: newswise.com
Published on 2024-09-19